Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KaiNETIC-3: KAI-9531 versus semaglutide and placebo in adults with obesity without diabetes
2025-523511-11-00Phase 3Authorised
- Sponsor
- Kailera Therapeutics
- Start
- Jun 2026
- Modality
- Small Molecules, Peptides
- Countries
- 5
01
Overview
Phase 3, randomised, single-blind trial of HRS9531 in obesity (3 arms), sponsored by Kailera Therapeutics. Primary endpoint: Percent change in body weight from baseline at Week 76. Planned start Jun 2026; status: authorised.
02
Drugs
HRS9531
03
Conditions
obesity
Beyond the preview
Go deeper on 2025-523511-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523511-11-00.